attend the 17th International Conference on Pharmaceutical Medicine (ICPM 2014). It is an international forum for pharmaceutical physicians, pharmaceutical medicine professionals and clinical research experts world-wide who are involved in the discovery, development, evaluation, registration, monitoring and marketing of medicines.
17th International Conference on Pharmaceutical Medicine
30. Jahreskongress der DGPharMed
– Berlin, Germany, March 20th - 21st, 2014 –
SMART DEVELOPMENT FOR BETTER DRUGS | WWW.ICPM2014.COM
Dear Colleague
Dear Clinical Research and Pharmaceutical Medicine Professional
We warmly invite you to attend the 17th International Conference on Pharmaceutical Medicine (ICPM 2014). It is an international forum for pharmaceutical physicians, pharmaceutical medicine professionals and clinical research experts world-wide who are involved in the discovery, development, evaluation, registration, monitoring and marketing of medicines.
3nd EXCERPT from the SCIENTIFIC PROGRAM
“Smart Development for Better Drugs”
«Drug development aiming for true innovations has become even more challenging in the past decade. The investments needed further increased, hurdles for approval and reimbursement became more demanding. In a globalized environment all economic regions are directly competing for R&D leadership in drug development.
The 17th International Conference on Pharmaceutical Medicine (ICPM 2014) will focus on the major framework conditions in that field.
Beyond assessment of the status quo the ICPM-2014-presentations will provide the participants with an outlook on what it will take to stay on top of drug development. High caliber international experts will address the key topics relevant for smart development of better drugs. However, the structure of ICPM 2014 will also allow for exchange and networking with peers to discuss presentations and new topics.» [*]
3nd GLANCE at BERLIN/GERMANY
“The World Is Our Partner”
«Berlin’s motto – “The World Is Our Partner” – already indicates its truly international spirit, which makes the German capital the place of choice for the ICPM 2014. Berlin is Germany’s largest city, with a population of about 3.4 million. It is a vibrant place with partnerships linking 17 cities and including many joint enterprises with places all around the world.
Berlin is one of the most dynamic economic regions in Europe. Its well-developed infrastructure, modern telecommunications structure and excellent science and research community provide ideal conditions for business and scientific meetings. Hotels and accommodation are state of the art and provide the perfect setting for such a conference at reasonable rates. We are confident that our guests will enjoy their stay at the ICPM 2014 in Berlin.» [*]
[* Dr. Axel Mescheder, President of the German Society of Pharmaceutical Medicine (‚Deutsche Gesellschaft für Pharmazeutische Medizin e.V.’ – DGPharMed – www.dgpharmed.de), Chairman of the Scientific Committee of ICPM 2014]
Addendum
ICPM 2014 is jointly organized by the ‘International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine’ (IFAPP – www.ifapp.org) and the German Society of Pharmaceutical Medicine (‚Deutsche Gesellschaft für Pharmazeutische Medizin e.V.’ – DGPharMed – www.dgpharmed.de). IFAPP and DGPharMed are independent non-profit organizations.
As an expert in clinical research and pharmaceutical medicine please share this information by forwarding this email to your colleagues or to any person or party or any other channel inside and outside your organization which might be interested in ICPM 2014 topics.
As a company and service provider in clinical research and pharmaceutical medicine – please consider to present your services and business at a booth at the ICPM 2014 exhibition. For more information please note the “Sponsorship & Exhibition Prospectus” (ICPM2014-Sponsorship.pdf) or contact the event organization, Katrin Schröder, at [email protected]
As a media representative please share this information with your colleagues, readers, viewers or listeners. For this purpose you are free to use the attached PDF “ICPM2014-Program.pdf” or parts of it in any way. Media representatives who wish to attend ICPM 2014 for reporting are kindly invited; they should call for accreditation without charge by email to the address indicated below. At ICPM 2014 the organizers offer information and help, if necessary, with establishing contacts to experts and representatives of IFAPP and DGPharMed.
For the program, registration and other issues please visit the ICPM 2014 Website at WWW.ICPM2014.COM
With kind regards
Yil-Seob Lee, MD, PhD, South Korea, IFAPP President, ICPM 2014 Organizer
Axel Mescheder, MD, PhD, Germany, DGPharMed President, ICPM 2014 Organizer
Kurt Bestehorn, MD, PhD, Germany, for the ICPM 2014 Organizers, Head of the Public Relation Team
DGPharMed
Olschewskibogen 7
80935 Munich – GERMANY
email: [email protected]
Eckhard Boettcher-Buehler, Germany, for the ICPM 2014 Public Relation Team
Science Writer | Intelligible Science | Medical Communication
Member of the German ‘Working Party of Medical Publicist – Club of Science Journalists’
www.boebue.de
phone: +49 172 – 836 20 22
email: [email protected]
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.